vs
Side-by-side financial comparison of Cherry Hill Mortgage Investment Corp (CHMI) and Spero Therapeutics, Inc. (SPRO). Click either name above to swap in a different company.
Spero Therapeutics, Inc. is the larger business by last-quarter revenue ($12.6M vs $11.8M, roughly 1.1× Cherry Hill Mortgage Investment Corp). On growth, Spero Therapeutics, Inc. posted the faster year-over-year revenue change (24080.8% vs -37.2%). Over the past eight quarters, Spero Therapeutics, Inc.'s revenue compounded faster (847.7% CAGR vs -15.2%).
Cherry Hill Mortgage Investment Corp is a U.S.-headquartered real estate finance firm focused on acquiring, investing in and managing residential mortgage-related assets. Its core holdings include agency mortgage-backed securities, residential loans and mortgage servicing rights, operating primarily in the U.S. domestic housing finance market.
CHMI vs SPRO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $11.8M | $12.6M |
| Net Profit | — | $31.5M |
| Gross Margin | 78.9% | — |
| Operating Margin | 72.1% | — |
| Net Margin | — | 250.7% |
| Revenue YoY | -37.2% | 24080.8% |
| Net Profit YoY | — | 250.9% |
| EPS (diluted) | $0.18 | $0.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $11.8M | $12.6M | ||
| Q3 25 | $8.6M | $0 | ||
| Q2 25 | $6.0M | $0 | ||
| Q1 25 | $-3.0M | $12.0K | ||
| Q4 24 | $18.7M | $52.0K | ||
| Q3 24 | $-7.1M | $65.0K | ||
| Q2 24 | $6.6M | $114.0K | ||
| Q1 24 | $16.3M | $140.0K |
| Q4 25 | — | $31.5M | ||
| Q3 25 | $4.5M | $-7.4M | ||
| Q2 25 | $1.6M | $-1.7M | ||
| Q1 25 | $-7.0M | $-13.9M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-12.4M | $-17.1M | ||
| Q2 24 | $784.0K | $-17.9M | ||
| Q1 24 | $12.1M | $-12.7M |
| Q4 25 | 78.9% | — | ||
| Q3 25 | 73.2% | — | ||
| Q2 25 | 67.7% | — | ||
| Q1 25 | 183.4% | — | ||
| Q4 24 | 83.3% | — | ||
| Q3 24 | 145.3% | — | ||
| Q2 24 | 47.5% | — | ||
| Q1 24 | 83.9% | — |
| Q4 25 | 72.1% | — | ||
| Q3 25 | 56.0% | — | ||
| Q2 25 | 44.4% | — | ||
| Q1 25 | 223.6% | -122758.3% | ||
| Q4 24 | 76.2% | — | ||
| Q3 24 | 171.8% | -28604.6% | ||
| Q2 24 | 22.0% | -16720.2% | ||
| Q1 24 | 78.0% | -9987.1% |
| Q4 25 | — | 250.7% | ||
| Q3 25 | 52.7% | — | ||
| Q2 25 | 25.9% | — | ||
| Q1 25 | 229.2% | -115550.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | 175.8% | -26380.0% | ||
| Q2 24 | 11.9% | -15668.4% | ||
| Q1 24 | 73.7% | -9049.3% |
| Q4 25 | $0.18 | $0.56 | ||
| Q3 25 | $0.05 | $-0.13 | ||
| Q2 25 | $-0.03 | $-0.03 | ||
| Q1 25 | $-0.29 | $-0.25 | ||
| Q4 24 | $0.30 | — | ||
| Q3 24 | $-0.49 | $-0.32 | ||
| Q2 24 | $-0.06 | $-0.33 | ||
| Q1 24 | $0.32 | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $54.9M | $40.3M |
| Total DebtLower is stronger | $146.3M | — |
| Stockholders' EquityBook value | $236.0M | $59.0M |
| Total Assets | $1.5B | $68.9M |
| Debt / EquityLower = less leverage | 0.62× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $54.9M | $40.3M | ||
| Q3 25 | $55.4M | $48.6M | ||
| Q2 25 | $58.0M | $31.2M | ||
| Q1 25 | $47.3M | $48.9M | ||
| Q4 24 | $46.3M | $52.9M | ||
| Q3 24 | $50.2M | $76.3M | ||
| Q2 24 | $52.4M | $63.5M | ||
| Q1 24 | $47.5M | $82.3M |
| Q4 25 | $146.3M | — | ||
| Q3 25 | $148.0M | — | ||
| Q2 25 | $150.1M | — | ||
| Q1 25 | $150.1M | — | ||
| Q4 24 | $152.1M | — | ||
| Q3 24 | $151.8M | — | ||
| Q2 24 | $160.5M | — | ||
| Q1 24 | $167.5M | — |
| Q4 25 | $236.0M | $59.0M | ||
| Q3 25 | $233.1M | $26.5M | ||
| Q2 25 | $229.9M | $32.8M | ||
| Q1 25 | $226.6M | $33.8M | ||
| Q4 24 | $230.3M | $46.1M | ||
| Q3 24 | $236.7M | $65.5M | ||
| Q2 24 | $234.5M | $80.5M | ||
| Q1 24 | $247.0M | $96.2M |
| Q4 25 | $1.5B | $68.9M | ||
| Q3 25 | $1.5B | $54.2M | ||
| Q2 25 | $1.5B | $62.1M | ||
| Q1 25 | $1.4B | $77.7M | ||
| Q4 24 | $1.5B | $110.5M | ||
| Q3 24 | $1.6B | $135.2M | ||
| Q2 24 | $1.4B | $149.9M | ||
| Q1 24 | $1.4B | $167.7M |
| Q4 25 | 0.62× | — | ||
| Q3 25 | 0.63× | — | ||
| Q2 25 | 0.65× | — | ||
| Q1 25 | 0.66× | — | ||
| Q4 24 | 0.66× | — | ||
| Q3 24 | 0.64× | — | ||
| Q2 24 | 0.68× | — | ||
| Q1 24 | 0.68× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $19.1M | $-8.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | -0.26× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $19.1M | $-8.4M | ||
| Q3 25 | $-2.4M | $17.4M | ||
| Q2 25 | $12.5M | $-17.7M | ||
| Q1 25 | $682.0K | $-4.0M | ||
| Q4 24 | $-4.7M | $-23.4M | ||
| Q3 24 | $4.4M | $12.8M | ||
| Q2 24 | $4.1M | $-18.7M | ||
| Q1 24 | $-19.1M | $5.9M |
| Q4 25 | — | -0.26× | ||
| Q3 25 | -0.53× | — | ||
| Q2 25 | 7.98× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 5.18× | — | ||
| Q1 24 | -1.58× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
